[A20-68] Ravulizumab (atypical haemolytic uraemic syndrome) - Benefit assessment according to §35a Social Code Book V
Last updated 02.11.2020
Project no.:
A20-68
Commission:
Commission awarded on 28.07.2020 by the Federal Joint Committee (G-BA).
Report type:
Dossier assessment
Status:
Commission completed
Department/Division:
Drug Assessment
Topic:
Haematology
Indication:
| Patients with atypical haemolytic uraemic syndrome who weigh at least 10 kg and are complement inhibitor treatment-naive or have received eculizumab for at least 3 months and have responded to this drug |
Result of dossier assessment:
| Added benefit not proven due to a lack of suitable study data |
Note:
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
| Project no. | Title | Status |
|---|---|---|
| A22-115 | Ravulizumab (generalized myasthenia gravis) – Benefit assessment according to § 35a SGB V | Commission completed |
| A21-125 | Ravulizumab (paroxysmal nocturnal haemoglobinuria) - Benefit assessment according to §35a Social Code Book V | Commission completed |
| A23-50 | Ravulizumab (neuromyelitis optica spectrum disorder [NMOSD]) – Benefit assessment according to §35a Social Code Book V | Commission completed |